A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms AVANA
- Sponsors Centus Biotherapeutics
- 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2017 This study has been suspended in Spain as per European Clinical Trials Database.
- 12 Jul 2016 New trial record